Pfizer COVID-19 vaccine highly effective in adolescents
The Pfizer / BioNTech COVID-19 vaccine is highly effective in 12- to 15-year-olds, the companies announced today in a press release. None of the children who received the vaccine in a clinical trial developed COVID-19, and they all developed strong antibody responses. There were no serious side effects.
The study included 2,260 participants. Around half received the two-dose vaccine, and the other half received placebo injections. There were 18 cases of COVID-19 found in the placebo group and none in the vaccine group.
Based on the study, the vaccine was 100 percent effective in this age group. The study was small, though, so it’s difficult to say if that number will hold up in a larger group. “But obviously, it looks good for the…